Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
45 巻, 2 号
選択された号の論文の22件中1~22を表示しています
EDITORIALS
ORIGINAL ARTICLES
  • Noritake Hata, Nobuaki Kobayashi, Takahiro Imaizumi, Shinya Yokoyama, ...
    2006 年 45 巻 2 号 p. 45-50
    発行日: 2006年
    公開日: 2006/02/15
    ジャーナル オープンアクセス
    Objective: The aim of this study was to clarify whether a helicopter ambulance system (doctor helicopter system; DHS) could shorten the time interval to coronary intervention in the treatment of patients with acute myocardial infarction (AMI), in comparison with ground ambulance (GA).
    Methods: The time from the emergency call to coronary angiography (CAG time) or to percutaneous coronary intervention (PCI time), and the inhospital outcome were evaluated in 76 AMI patients. Twenty patients were transported by DHS, and the other 56 were by GA.
    Results: Both CAG time and PCI time were significantly shorter in the DHS (98.8+/-29.2 min, and 169.6+/-57.4 min) than those of the GA (126.6+/-48.7 min, and 203.2+/-57.0 min; p<0.05) group. Inhospital mortality was lower in the DHS (5.0%) versus the GA (10.7%) group.
    Conclusion: Use of DHS shortened the time interval to coronary intervention and also improved the inhospital prognosis of AMI patients.
  • Michiro Ishikawa, Atsushi Namiki, Tetsuya Kubota, Suguru Yajima, Masay ...
    2006 年 45 巻 2 号 p. 51-55
    発行日: 2006年
    公開日: 2006/02/15
    ジャーナル オープンアクセス
    Objective: The aim of this study was to assess the effects of hydrophilic pravastatin and lipophilic atorvastatin on glucose metabolism and lipid metabolism in nondiabetic patients with hypercholesterolemia.
    Methods: Fasting plasma glucose (FPG), hemoglobin A1c (HbA1c), total cholesterol (TC), lowdensity lipoprotein cholesterol (LDLC), highdensity lipoprotein cholesterol (HDLC), and triglyceride (TG) levels were determined before and after statin treatment.
    Patients: A total of 44 nondiabetic patients (FPG ≤125 mg/mL; HbA1c <5.8%) undergoing treatment with either pravastatin (n=21) or atorvastatin (n=23) for hypercholesterolemia were investigated.
    Results: FPG level in the pravastatin but not atorvastatin group was significantly lowered after vs before treatment. Accordingly, the HbA1c level in the atorvastatin but not in the pravastatin group was significantly increased. As expected, both TC and LDLC levels were significantly lowered in both groups. In particular, the TC level in the atorvastatin group was more remarkably and significantly improved than in the pravastatin group. On the other hand, the HDLC level in the pravastatin group but not in the atorvastatin group was significantly increased after the administration period. The TG level was unaffected in both groups.
    Conclusion: Pravastatin was suggested to act favorably, while atorvastatin adversely, regarding it's effects on glucose metabolism in nondiabetic hypercholesterolemic patients, although atorvastatin exerted more potent cholesterollowering effects compared with pravastatin.
  • Jun Nagano, Yukito Ichinose, Hiroshi Asoh, Jiro Ikeda, Akira Ohshima, ...
    2006 年 45 巻 2 号 p. 57-63
    発行日: 2006年
    公開日: 2006/02/15
    ジャーナル オープンアクセス
    Objective: To examine predictive values for the effect of the "Type 1" (hopeless and emotionsuppressive, cancer prone), "Type 4" (autonomous, healthy), and "Type 5" (rational/antiemotional, cancer prone) personalities proposed by GrossarthMaticek on the prognosis of lung cancer patients.
    Methods: 68 lung cancer patients were scored on the Types 1, 4, and 5 personality scales of the Short Interpersonal Reactions Inventory and were followed until the date of death or were censored at a maximum of 5.7 years after entry.
    Results: The stage at diagnosis tended to be higher in patients with a high Type 1 or a low Type 4 score. A univariate Cox proportional hazards model showed that a high tendency toward Type 1 or Type 5 was related to an increased hazard of death. Adjustment for age, performance status, and stage, however, attenuated the relation to Type 1, leaving only Type 5 as a significantly related personality factor.
    Conclusion: A high Type 5 tendency may predict poor survival in lung cancer patients, whereas Types 1 and 4 may not be independent predictors.
  • Koji Kishi, Hiroyuki Nakamura, Katsuyuki Kobayashi, Toshio Hashimoto, ...
    2006 年 45 巻 2 号 p. 65-72
    発行日: 2006年
    公開日: 2006/02/15
    ジャーナル オープンアクセス
    Objective: Radiofrequency ablation (RFA) is frequently used for hepatic malignant tumors, but few reports discuss its use for lung tumors. We report our pilot clinical study with RFA for the treatment of pulmonary malignant tumors.
    Patients and Methods: Five patients with histologicallyproven malignant primary and three metastatic lung tumors underwent a total of 11 RFA procedures. RFA was performed in two patients as palliative therapy to shrink the tumors and in six as radical therapy. All RFA was performed by the percutaneous CTguided approach.
    Results: Three tumors were completely ablated by one procedure. Contrast CT revealed cyst cavity formation or scar formation at these three tumors. Gd contrastenhanced MRI revealed cystic lesions with ringlike enhancement or scar formation. Partial ablation after the first procedure was noted in six tumors including the two palliative cases. RF ablation was well tolerated in all patients. Intraprocedural complications included six cases of pneumothorax (one patient required chest tube placement), six cases of pleural effusion (two patients required chest tube placement), one case of pneumonia (improved immediately with antibiotics), three cases of bloody sputum (mild), and six cases of chest pain (all cases after the procedure).
    Conclusions: This pilot clinical study demonstrates that CTguided RFA is a relatively safe and effective treatment option for malignant lung tumors. Additional trials are needed to determine the safety, efficacy, and optimal indications of RFA.
CASE REPORTS
SHORT COMMUNICATION
PICTURES IN CLINICAL MEDICINES
feedback
Top